Skip to main content
Bipin Savani, MD, Oncology, Nashville, TN, Vanderbilt University Medical Center

BipinNSavaniMD

Oncology • Nashville, TN

Hematologic Oncology

Professor, Medicine, Vanderbilt University School of Medicine

Join to view full profile

Dr. Savani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Savani's full profile

Already have an account?

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2003 - 2007
  • UMass Chan Medical School
    UMass Chan Medical SchoolResidency, Internal Medicine, 2001 - 2003
  • B. J. Medical College Ahmedabad
    B. J. Medical College AhmedabadClass of 1989

Certifications & Licensure

  • NH State Medical License
    NH State Medical License 2003 - Present
  • TN State Medical License
    TN State Medical License 2007 - 2024
  • MD State Medical License
    MD State Medical License 2003 - 2013
  • AR State Medical License
    AR State Medical License 2006 - 2011
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • The European Society for Blood and Marrow Transplantation (EBMT) Consensus Recommendations for Donor Selection in Haploidentical Hematopoietic Cell Transplantation  
    Leo Luznik, Karen Ballen, Asad Bashey, Hillard M Lazarus, Bipin N Savani, Rizwan Romee, Ephraim J Fuchs, Nature
  • Prophylactic Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplantation in Acute Leukaemia – a Matched Pair Analysis by the Acute Leukaemia Working Party of ...  
    Bipin Savani, MD, British Journal of Haematology
  • Post-Remission Strategies for the Prevention of Relapse Following Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia: Expert Review fro...  
    Catherine J Lee, Bipin N Savani, Nature
  • Join now to see all

Abstracts/Posters

  • Impact of Renal Dysfunction Measured By Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT)
    Bipin N. Savani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia
    Bipin N. Savani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell TransplantationClinically Relevant Abstract
    Bipin N. Savani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Inferior Outcome of Allogeneic Stem Cell Transplantation in First Complete Remission for Secondary AML As Compared to De Novo Disease: Results from a Retrospective, Re... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia in First Complete Remission Undergoing Allogeneic Stem Cell Transplantation from 10/10 HLA-Matched Unrelated Donors
    Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia in First Complete Remission Undergoing Allogeneic Stem Cell Transplantation from 10/10 HLA-Matched Unrelated DonorsJuly 3rd, 2020

Professional Memberships

Hospital Affiliations

Dr. Bipin Savani, Dr. Bipin Savani, MD, Dr. B Savani, Dr. Bipin N Savani